Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

The FDA approved vutrisiran for the treatment of transthyretin ... decreasing deposition of transthyretin fibrils. These fibrils form the amyloid protein, which is associated with CV damage ...

A bill under consideration in the legislature would position Iowa to immediately allow prescriptions of a synthetic version ...

INSIDE INFORMATIONREGULATED INFORMATIONFDA Issues Nyxoah an Approvable Letter for its Genio® SystemMont-Saint-Guibert, Belgium – March 26, 2025, ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...